Unravelling neuroendocrine disease

Cortene is a clinical stage biopharmaceutical company, applying its expertise of the neuroendocrine system to develop therapies for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and related diseases.

COVID-19

Coronavirus could trigger post-viral fatigue syndromes similar to that following the SARS 2002/3 outbreak, in which up to 40% of survivors had ongoing ME/CFS-like symptoms (with 27% meeting the CDC’s criteria for ME/CFS) 4 years later[1]. There is evidence that 10% of COVID-19 patients experience a prolonged recovery lasting longer than 100 days that includes ongoing ME/CFS-like symptoms[2]. These patients are being referred to as the long haulers. Cortene’s pioneering treatment for ME/CFS could be an important treatment for this condition.